Denis Kay - Alpha Cognition Chief Officer
| ACOGF Stock | USD 6.62 0.05 0.75% |
Insider
Denis Kay is Chief Officer of Alpha Cognition
| Age | 66 |
| Web | https://www.alphacognition.com |
Alpha Cognition Management Efficiency
The company has return on total asset (ROA) of (1.6088) % which means that it has lost $1.6088 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.9694) %, meaning that it generated substantial loss on money invested by shareholders. Alpha Cognition's management efficiency ratios could be used to measure how well Alpha Cognition manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| George Hill | Ascletis Pharma | 72 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Ming CPA | Ascletis Pharma | N/A | |
| Hejingdao Wu | Ascletis Pharma | 49 | |
| Philippe Slos | Transgene SA | N/A | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Mark Gowland | Fennec Pharmaceuticals | N/A | |
| Steven RPh | Transgene SA | 61 | |
| Handan He | Ascletis Pharma | 61 | |
| Kristjan Gudmundsson | Ascletis Pharma | 55 | |
| LLM JD | Transgene SA | 53 | |
| Gaelle Stadtler | Transgene SA | 40 | |
| Jinzi Wu | Ascletis Pharma | 60 | |
| Yuemei Yan | Ascletis Pharma | 53 | |
| Hedi Brahim | Transgene SA | 42 | |
| Gustavo Scaffa | ImmuCell | N/A | |
| John MBA | Ascletis Pharma | N/A | |
| Maud MD | Transgene SA | 69 | |
| Lucie Larguier | Transgene SA | N/A | |
Management Performance
| Return On Equity | -6.97 | |||
| Return On Asset | -1.61 |
Alpha Cognition Leadership Team
Elected by the shareholders, the Alpha Cognition's board of directors comprises two types of representatives: Alpha Cognition inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpha. The board's role is to monitor Alpha Cognition's management team and ensure that shareholders' interests are well served. Alpha Cognition's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpha Cognition's outside directors are responsible for providing unbiased perspectives on the board's policies.
| LLB BA, Special Founder | ||
| Colleen Johns, VP Devel | ||
| Lauren MBA, Chief Officer | ||
| Denis Kay, Chief Officer | ||
| Donald BA, Chief Officer | ||
| Michael McFadden, CEO Director | ||
| MBA MD, Chief Officer |
Alpha Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Alpha Cognition a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.97 | |||
| Return On Asset | -1.61 | |||
| Current Valuation | 14.92 M | |||
| Shares Outstanding | 61.02 M | |||
| Shares Owned By Insiders | 29.84 % | |||
| Shares Owned By Institutions | 0.73 % | |||
| Price To Book | 9.90 X | |||
| Gross Profit | (37.5 K) | |||
| EBITDA | (18.93 M) | |||
| Net Income | (19.55 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Alpha OTC Stock
Alpha Cognition financial ratios help investors to determine whether Alpha OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alpha with respect to the benefits of owning Alpha Cognition security.